AtCor Medical - Analysts Reports

CONTACT US SITE MAP SEARCH

Home / Investors / Analysts' Reports

Analysts' Reports

Analysts' Reports

RB Milestone Group

27 October 2009

Strong Growth Prospects with Multi-market Opportunities of $2.1 billion

The Australian Investor

4 February 2009

AtCor Medical Significantly Progresses Towards its Goal of a Long Term, Financially Stable Position

Bioshares

23 January 2009

Atcor Medical – Higher Sales Growth Anticipated

Taylor Collison

19 February 2010

Average 1H, But CP Thematic Growing in Strength

29 October 2009

Central Pressure Paradigm Drawing Ever Closer

21 August 2009

No Surprises Post July FY09 Result Preview; Pharma Contracts Remain the Driver

27 July 2009

Grows FY09 Product Sales by 74%

19 May 2009

Second FY Sales Upgrade Builds Confidence

15 April 2009

Additional US$0.8m in Pharma Contracts Underscores Defensive Model

2 April 2009

New Application Potential for SphygmoCor

20 February 2009

1H09 Maiden NPAT of $0.2m; Outlook Remains Solid

14 November 2008

Major Clinical Endorsement Continues; FY09 Sales Upgrade

4 November 2008

US$4.2m in Pharma Trial Contracts since June

10 June 2008

Central Pressure Measurement: The Next Major Medical Paradigm Shift?

21 May 2008

Russian Approval; Major Clinical Evidence Underpins SphygmoCor® Opportunity

11 March 2008

Initiating Coverage; Valuation Metrics Too Attractive to Ignore